What Does “Beyond the Pill” Mean?

A solution qualifies as Beyond the Pill if it meets one of two criteria: 1.It supports HCPs beyond the prescription and strengthens the HCP/Pharma relationship — helping clinicians engage with the right information, identify eligible patients, make better clinical decisions, and reduce administrative burden. 2.It supports patients beyond the drug — helping patients stay adherent, manage their conditions, replace the drug, change health behaviors, and generate real-world data that demonstrates therapy value. Together, these form the core of the BtP ecosystem. Many other solutions use the Beyond the Pill label whenever it helps their sales and marketing efforts.

The Five BtP Categories

1. Digital HCP Engagement Platforms

• Next-best-action detailing — AI-driven message, channel, and timing recommendations
• Medical information on-demand — compliant, instant drug query answers via NLP/LLMs
• Virtual CME & advisory boards — accredited education at scale
• KOL mapping & engagement — data-driven identification of scientific leaders
• Field force optimization — improved rep productivity and targeting

2. Patient Identification & Diagnosis Enablement

• Undiagnosed case finding — mining EHR/claims data for unrecognized patients
• Biomarker & genomic scoring — matching molecular profiles to therapies
• Clinical trial matching — aligning patient data with study criteria
• Care-gap closure — identifying missed screenings or therapy opportunities
• Switch-risk prediction — forecasting therapy discontinuation

3. Clinical Decision Support & Workflow Automation

• Therapy selection navigators — ranking options based on guidelines + patient factors
• Dosing & titration optimization — safe dose adjustments over time
• Toxicity & AE management — evidence-based intervention guidance
• Diagnostic image & signal triage — flagging suspicious findings
• Prior-authorization automation — streamlining reimbursement

4. Patient Adherence & Support Programs (PSPs)

• Companion apps & reminders — dose tracking, logs, habit building
• Behavioral nudging & gamification — rewards and progress tracking
• AI coaching & education — multilingual, always-on clinical communication
• Onboarding & device training — guiding first-use of inhalers, injectors, devices
• Access & financial assistance — automating co-pay and enrollment

5. Remote Monitoring & Digital Therapeutics

• Disease-specific RPM — continuous vital sign and symptom tracking
• Digital therapeutics (DTx) — software-based adjuncts to drug treatment
• Symptom & PRO capture — structured patient-reported outcomes between visits
• Telehealth escalation — routing patients to clinicians with context
• Early-warning algorithms — detecting deterioration before complications

Six Must-Have Requirements for Best-in-Class BtP Solutions

1.Clear Business Model Aligned with BtP Definition. The vendor’s revenue model must directly connect to its role in the therapy lifecycle — either supporting HCPs or patients beyond the prescription. Must be pharma-compatible with enterprise B2B structure, clear SLAs, and flexibility across SaaS, per-patient, project-based, and outcome-linked models. Red flag: pharma as an afterthought to consumer or hospital revenue. 2.Proven Pharma Collaboration & Clear Pricing. Prior pharma experience is the strongest signal that a vendor understands cross-functional decision-making, MLR processes, pharmacovigilance, and enterprise procurement. Must present clear pricing for all stakeholders (pharma, hospitals, payers) — including how costs scale with volume, geography, and integration complexity. Best-in-class: named multi-year partnerships and pricing refined through actual contracts. 3.Clinical Evidence Generation. Must demonstrate measurable clinical or commercial impact, not just engagement metrics. Evidence hierarchy: peer-reviewed RCTs (strongest), third-party validated data (strong), controlled pilots (acceptable), vendor claims only (weakest). Best-in-class solutions quantify improvements in clinical endpoints, health-economic impact, or real-world evidence supporting regulatory submissions and payer negotiations. 4.Regulatory & Compliance Maturity. HIPAA compliance (US) and GDPR compliance (EU) are non-negotiable. Medical device classification must be clear and appropriate — CE marking under MDR or FDA SaMD clearance where the solution’s function requires it. ISO 13485, ISO 27001, and cybersecurity audits expected. EU AI Act high-risk obligations (2026–2027) must be anticipated. Solutions positioned solely as consumer wellness products lack credibility for global pharma partnerships. 5.Integration Capability. Solutions should integrate into healthcare ecosystems rather than operating standalone. Key dimensions: FHIR/HL7 interoperability for EHR data exchange, CRM connectivity (Veeva, Salesforce) for HCP-facing solutions, pharmacy/payer/wearable integration for patient-facing solutions, and workflow fit — the solution must work within existing clinical and patient routines without requiring behavior change. 6.Proven Usage & Scalability. Must demonstrate active real-world adoption by HCPs and/or patients — not just downloads or deployments. Sustained retention rates (30-day, 90-day) connected to outcomes. Scalability requires cloud-native infrastructure, multi-language support (5–6+ languages), white-label capability, multi-jurisdiction regulatory readiness (MDR, FDA SaMD), and enterprise SLAs. Best-in-class vendors connect usage data to measurable outcomes.

R2GConnect’s Partner Fit Scoring Framework

The evaluation and selection process of a BtP vendor is complex and time consuming. R2GConnect recommends a Partner Fit Scoring Framework — a weighted evaluation model producing a composite score (0–100) for each vendor. Weights should be adjusted at the beginning of each vendor selection process: Evidence Level (20%): Peer-reviewed RCT (100), third-party validated pilot (75), vendor claims only (50), no evidence (25). Technical Maturity / Innovation Level (20%): FDA/CE cleared or enterprise-deployed (100), CE Class I with active deployments (50–75), prototype (<50). Regulatory & Compliance (10%): Full HIPAA+GDPR with appropriate device classification and ISO certifications (100). Partial compliance (60–80). No regulatory posture (<50). Integration Flexibility (10%): FHIR/HL7 + EHR/CRM proven across multiple systems (100), partial API-based (60–80), standalone (<50). Market Reach & Proven Usage (10%): Multi-country pharma deployments with demonstrated adoption and enterprise SLAs (100), regional pilot (60–80), single-market no adoption (<50). Therapeutic Relevance (10%): Multi-therapy platform (100), deep specialty with expansion potential (70–80), narrow single-use (50). Team Fit (20%): Vendor team quality and motivation are critical, particularly given partnerships extending one to two years minimum. Pharma companies require partners who demonstrate resilience, proactive communication, and the ability to sustain collaboration during demanding phases of the partnership.

Takeaway

Beyond-the-pill solutions can generate measurable value for pharma; however, vendor selection remains complex due to the lack of a consistent definition. The broad and often inaccurate use of the BtP label allows healthtech companies to position offerings within this category even when BtP is not a core capability or when value claims are not substantiated. To mitigate this, pharma companies need to clearly define the specific outcomes and value drivers they expect from a BtP partnership and assess potential vendors against structured, best-in-class criteria. R2GConnect’s BtP vendor selection framework addresses this need by enabling decision-makers to systematically identify, benchmark, and select the most suitable partners across five solution categories — ensuring cross-functional alignment and measurable, outcome-driven impact.

To see leading BtP solutions in action, R2GConnect is hosting an online BtP pitch event on April 14, showcasing best-in-class solution providers evaluated through this framework.

For more information, contact hello@research2guidance.com or visit r2gconnect.com/innovation-scouting